Other therapeutic targets with similar mechanisms of action, including monoclonal antibodies against C5a (vilobelimab) currently tested in adult GPA/MPA and IL-5 blockade (benralizumab and depemokimab, both compared with mepolizumab in head-to-head clinical trials in adults with EGPA), are emerging [130]. Here, IL5 is linked to eosinophilic granulomatosis with polyangiitis.